Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome

被引:47
作者
Hoffman, WH
Jueppner, HW
DeYoung, BR
O'Dorisio, MS
Given, KS
机构
[1] Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02114 USA
[3] Univ Iowa, RJ & LA Carver Coll Med, Dept Pathol, Iowa City, IA USA
[4] Univ Iowa, RJ & LA Carver Coll Med, Dept Pediat, Iowa City, IA USA
[5] Med Coll Georgia, Dept Surg, Augusta, GA 30912 USA
关键词
fibroblast growth factor-23; hypophosphatemic rickets; linear nevus sebaceous syndrome; octreotide; tumor-induced osteomalacia;
D O I
10.1002/ajmg.a.30599
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We report on an adolescent who experienced the onset of linear nevus sebaceous syndrome (LNSS) prior to 1 year of age. At 7 years of age he was diagnosed to have hypophosphatemic rickets. He was suboptimally controlled with phosphate and calcitriol treatment and sustained numerous insufficiency fractures ipsilateral to the linear sebaceous nevus. Fibroblast growth factor-23 (FGF-23), the phosphaturic peptide, was elevated in the plasma. Treatment with the somatostatin agonist, octreotide, and excision of the nevus were followed by normalization of FGF-23 and clinical improvement. The patient also had hyperimmunoglobulinemia E, which responded to octreotide and surgery. We speculate that in some patients with LNSS there may be more than one mediator of hypophosphatemia and that FGF-23 is the mediator of hyperphosphaturia in this and other hypophosphatemic syndromes. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:233 / 236
页数:4
相关论文
共 41 条
[31]   FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting [J].
Riminucci, M ;
Collins, MT ;
Fedarko, NS ;
Cherman, N ;
Corsi, A ;
White, KE ;
Waguespack, S ;
Gupta, A ;
Hannon, T ;
Econs, MJ ;
Bianco, P ;
Robey, PG .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (05) :683-692
[32]   Octreotide therapy for tumor-induced osteomalacia [J].
Seufert, J ;
Ebert, K ;
Müller, J ;
Eulert, J ;
Hendrich, C ;
Werner, E ;
Schütze, N ;
Schulz, G ;
Kenn, W ;
Richtmann, H ;
Palitzsch, KD ;
Jakob, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (26) :1883-1888
[33]   Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia [J].
Shimada, T ;
Mizutani, S ;
Muto, T ;
Yoneya, T ;
Hino, R ;
Takeda, S ;
Takeuchi, Y ;
Fujita, T ;
Fukumoto, S ;
Yamashita, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (11) :6500-6505
[34]   HYPOPHOSPHATEMIC RICKETS IN LINEAR SEBACEOUS NEVUS SEQUENCE [J].
SKOVBY, F ;
SVEJGAARD, E ;
MOLLER, J .
JOURNAL OF PEDIATRICS, 1987, 111 (06) :855-857
[35]  
WEIDNER N, 1985, CANCER-AM CANCER SOC, V55, P1691, DOI 10.1002/1097-0142(19850415)55:8<1691::AID-CNCR2820550814>3.0.CO
[36]  
2-S
[37]   Monoclonal gammopathy and spurious hypophosphatemia [J].
Weisbord, SD ;
Chaudhuri, A ;
Blauth, K ;
DeRubertis, FR .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2003, 325 (02) :98-100
[38]   The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting [J].
White, KE ;
Jonsson, KB ;
Carn, G ;
Hampson, G ;
Spector, TD ;
Mannstadt, M ;
Lorenz-Depiereux, B ;
Miyauchi, A ;
Yang, IM ;
Ljunggren, Ö ;
Meitinger, T ;
Strom, TM ;
Jüppner, H ;
Econs, MJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) :497-500
[39]   ONCOGENIC OSTEOMALACIA - EVIDENCE FOR A HUMORAL PHOSPHATURIC FACTOR [J].
WILKINS, GE ;
GRANLESSE, S ;
HEGELE, RG ;
HOLDEN, J ;
ANDERSON, DW ;
BONDY, GP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (05) :1628-1634
[40]   Hypophosphatemic rickets accompanying McCune-Albright syndrome: evidence that a humoral factor causes hypophosphatemia [J].
Yamamoto, T ;
Miyamoto, K ;
Ozono, K ;
Taketani, Y ;
Katai, K ;
Miyauchi, A ;
Shima, M ;
Yoshikawa, H ;
Yoh, K ;
Takeda, E ;
Okada, S .
JOURNAL OF BONE AND MINERAL METABOLISM, 2001, 19 (05) :287-295